District court hears Amgen, Sandoz biosimilars case

The U.S. District Court for the Northern District of California on Friday accepted motions in the biosimilars dispute between Amgen Inc. (NASDAQ:AMGN) and the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that could potentially set a precedent for the biosimilar application process in the U.S.

Amgen submitted a motion for a preliminary injunction that would prevent Sandoz from marketing Zarxio filgrastim-sndz, a biosimilar of Amgen's Neupogen filgrastim methionyl human G-CSF. ...